NEW YORK (GenomeWeb News) – Ariadne said today it is collaborating with European consortium BIO-NMD on a project to identify biomarkers for Duchenne and Becker muscular dystrophies and collagen VI myopathies.
Ariadne will provide bioinformatics tools for identifying functional pathways, potential targets, and data outflow integration, the company said in a statement. Its software suit, Pathway Studio, will be the core product used for integrating data and information flow.